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Background: Intralumenal bacteria play a critical role in the pathogenesis of acute infective 
episodes and airway inflammation. Antigens from colonizing bacteria such as nontypeable 
Haemophilus influenzae (NTHi) may contribute to chronic lung disease through an immediate 
hypersensitivity response. The objective of this study was to determine the presence of specific 
NTHi-IgE antibodies in subjects with chronic bronchitis (CB) and COPD who had smoked.
Methods: Serum, sputum, and saliva samples were collected from subjects with CB and 
moderate–severe COPD and healthy aged-matched controls. Total IgE and specific NTHi IgE 
were measured by enzyme linked immmunosorbent assay. Throat swabs were examined for 
the presence of NTHi.
Results: The results demonstrate that: i) specific NTHi IgE antibodies occur at a low level in 
healthy subjects; ii) those with both CB and moderate–severe COPD have elevated specific 
NTHi IgE antibody compared with healthy controls, with higher levels in those with most 
severe disease; iii) IgE levels are greater in those with moderate–severe COPD than in those 
with CB. They demonstrate specific NTHi IgE antibody is regularly found at higher than normal 
levels in COPD.
Conclusion: The detection of IgE antibody to colonizing bacteria in all subjects with CB or 
moderate–severe COPD identifies a possible mechanism of bronchospasm in these subjects 
amenable to specific intervention therapy.
Keywords: nontypeable Haemophilus influenza, chronic bronchitis, chronic obstructive 
pulmonary disease, IgE, smoking
Introduction
Chronic airways disease related to inhalation of noxious material (smoking or 
environmental pollution) is a major health issue. In its extreme form, COPD is 
becoming an increasing cause of global mortality.1 COPD is characterized by 
progressive irreversible airflow limitation, and destruction of the gas exchange 
  apparatus. These changes are associated with evidence of an inflammatory response2 
characterized by cellular infiltrate,3 mucus secretion,4 and structural remodeling.5 
While subjects can remain undiagnosed and without clinical evidence of lung dis-
ease until they have advanced COPD, many have a history of symptomatic disease 
evidenced as chronic cough and sputum (chronic bronchitis, CB) and/or recurrent 
episodes of acute wheezy bronchitis, and/or late onset reversible airways disease 
(‘intrinsic asthma’). The relationship between these entities is complex and not well 
understood, with no obligatory linkage with COPD. A classical model identifies the 
extremes of ‘completely reversible airways obstruction’ (asthma) and irreversible International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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airways obstruction (COPD),6 though clinical experience 
recognizes a more complex mixed picture. For example, 
airway hyper-responsiveness is   commonly present in COPD 
contributing to symptoms such as breathlessness, wheeze, 
and increased cough.7   Linkage exists between smoking and 
recurrent acute wheezy bronchitis.8 Intrabronchial infection 
has been postulated as a major promoter of intrabronchial 
inflammation,9 with nontypeable Haemophilus influenzae 
(NTHi) as the most common and when present the most 
dominant pathogenic bacterium.9,10 A direct correlation 
exists between colonization of the lower airways, the level 
of airways obstruction, and   cigarette smoking status.11 NTHi 
directly damages the bronchus mucosa9 and is claimed 
to mediate acute infective episodes.12 Its role in causing 
progressive reversible or   irreversible airways obstruction, 
however, remains debated.13,14 Recent studies indicate a 
critical role for colonizing NTHi in the pathogenesis of 
acute exacerbations of COPD and demonstrate that oral 
immunotherapy with NTHi reduces the level of colonization 
in the airways as well as the incidence and severity of acute 
exacerbations.15,16 The detection of higher levels of IgE in 
the serum of subjects with COPD,17 and the observation that 
NTHi triggers histamine release through both IgE- and non-
IgE-dependent mechanisms18 from cells contained within the 
respiratory mucosal sensitized to the bacterium,19,20 suggests 
a role for NTHi also in the development of the reversible 
component of airways obstruction found in smoking-related 
airways disease. Detection of anti-bacterial IgE antibody and 
eosinophils in the bronchus lumen21 adds support to this con-
cept that immediate hypersensitivity to colonizing bacteria 
contributes to bronchial disease. As detection of specific IgE 
antibody against NTHi antigens in airway secretions as well 
as blood is critical to the development of this hypothesis, 
two groups, one with CB and wheeze associated with acute 
exacerbations, and a second, with moderate-severe COPD, 
have been studied to determine the presence and amount of 
IgE anti-NTHi antibodies in blood, saliva, and sputum.
Materials and methods
subjects
Four groups of subjects were investigated: Group 1 CB – 11 
patients (23–61 years) $2-year history of recurrent acute 
wheezy bronchitis, and chronic cough and sputum, defined 
as CB by the Medical Research Council (MRC).22 Con-
trol 1 – age matched for group 1: 9 healthy subjects with 
normal lung function. Group 2 moderate–severe COPD – 17 
patients (44–77 years) with CB as defined by the MRC22 and 
the GOLD criteria for COPD.23 These subjects had chronic 
persistent irreversible airflow obstruction (FEV1 , 80% 
of predicted normal). Control 2 – age-matched for 
group 2: 9 healthy subjects with normal lung function. 
A clinical examination was made by a single consultant 
physician who assessed the subjects against the MRC22 and 
GOLD23 criteria in a   hospital outpatient clinic. A comprehen-
sive questionnaire was administered by a study nurse. The 
questionnaire included data on smoking, allergic disease, 
and respiratory symptoms (as per the ATS-DLD78). Lung 
function was assessed by spirometry. Subjects were excluded 
if they had a history of long-standing asthma (other than 
episodic wheezing bronchitis). Wheeze was defined as a 
wheezing or whistling sound in the chest. None of the sub-
jects studied had a respiratory infection within the preceding 
month of study, and all were clinically stable.
ethics approval and consent
Ethical approval for the study protocol was provided by the 
University of Newcastle Human Research Ethics Committee. 
All subjects gave written informed consent.
samples collected
Saliva was collected into chilled tubes by mild suction and clar-
ified by centrifugation. Blood was collected by   venipuncture, 
clotted, and the serum recovered by   centrifugation.   Sputum 
samples were obtained by a single expectoration during a 
morning visit to a hospital outpatient clinic and assessed for 
oropharyngeal contamination by microscopic examination.24 
Only subjects whose sputum samples contained 4 or more 
squamous epithelial cells per low field were included in the 
study. Sputum sol was prepared from acceptable samples 
by centrifugation. The samples were frozen at −70°C until 
analyzed. Throat swabs were collected. Sputum samples and 
throat swabs were cultured for NTHi.
Measurement of total IgE and specific 
nThi Ige antibodies
Total IgE and specific NTHi IgE antibodies were measured by 
enzyme linked immunosorbent assay (ELISA). Goat antihu-
man IgE (Biosource International-Tago Immunochemicals, 
Camarillo, CA) was used as the solid phase antigen for 
the measurement of total IgE in samples. The solid phase 
antigens, an outer membrane protein (OMP) preparation, 
and P6, a highly conserved 16-kDa lipoprotein, used for the 
measurement of bacteria-specific IgE were prepared from 
NTHi prepared as previously described.23,25 Briefly, the OMP International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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preparation was prepared by detergent solubilization of the 
outer membrane of the microbe and subsequent ethanol 
precipitation. P6 was prepared from the OMP preparation 
by preparative electrophoresis. The purity of the P6 antigen 
and the quality of the OMP preparation was characterized by 
sodium dodecyl-sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) carried out using the PHAST System (GE 
Healthcare, Buckinghamshire, UK).25,26 The P6 preparations 
were free of detectible bacterial endotoxin. The sensitivity 
range for total IgE was 0.15–2.43 ng/mL. The between-assay 
coefficient of variation for both total IgE and specific NTHi 
IgE antibodies ranged from 6%–9%. No cross-reactivity of 
the NTHi specific IgE ELISA was detected against other 
respiratory pathogens.
statistical analysis
A Chi-square (χ2) analysis was used to test for goodness of 
fit for each parameter measured. For data that were normally 
distributed analysis of differences between 2 individual 
groups were assessed by Student’s t-test. The data were 
expressed as mean and standard error. Where the data were 
of nonparametric distribution, differences between groups 
were assessed by a Mann–Whitney nonparametric test. The 
results were expressed as median and range.
Results
subjects
The subject groups were gender and age matched. None of the 
controls had smoked. Both the CB and COPD groups had a 
significant history of cigarette smoke exposure. Chest wheeze 
associated with acute bronchitis was characteristic of both 
the CB and COPD groups.
Microbial culture
Seventy percent of moderate–severe COPD subjects and 
36% of CB subjects were throat swab culture positive for 
NTHi. Only 1 of the 18 control subjects was throat swab 
culture   positive (Table 1). Fifty-six percent of moderate–
severe COPD subjects and 66% of mild CB subjects had 
positive sputum cultures for NTHi.
Total Ige
In subjects with CB the levels of total IgE in saliva and 
serum were similar to those observed in Control 1 group. 
However, in patients with moderate–severe COPD the level 
of total IgE in saliva was significantly greater than in Control 
2 group (8.5 vs 4.0 ng/mL, P , 0.005) and greater than that 
observed in the CB group (8.5 vs 5.0 ng/mL, P , 0.05). 
Total serum IgE was substantially elevated in moderate–
severe COPD subjects compared with Control 2 group, but 
this did not reach statistical significance (992 vs 490 ng/mL, 
P = 0.06). These serum levels were significantly greater than 
that observed in the mild COPD group (992 vs 438 ng/mL, 
P , 0.05). In sputum, total IgE levels in both study groups 
were similar (11.5 vs 11.8 ng/mL) (Table 2).
NTHi specific IgE antibodies to OMP
IgE NTHi OMP antibody was detected in the saliva, 
serum, and sputum of subjects with CB and in the serum 
of   Control 1 group. Antibody levels in the serum of the CB 
Table 1 Characteristics of study subjects
Group CB Control 1 COPD Control 2
number of subjects 11 9 17 9
gender (M:F) 7:4 5:4 11:7 6:3
Age (years)
Mean 46.7 43.0 64.4 67.2
range 23–61 23–62 44–79 52–77
Current smokers 9 0 2 0
Previously smoked 2 0 15 0
smoking exposure  
(cigarettes per day)
22 0 27 0
Wheezy bronchitis 9 0 15 0
FEV1 (L)
Mean 2.59 2.50 0.50a 1.94a
range 1.18–4.75 1.20–4.51 0.2–1.14 1.35–2.55
Throat swab nThi positive 4 0 12 1
sputum nThi positive 6 – 9 –
Note: aP , 0.005.
Abbreviations: CB, chronic bronchitis; nThi, nontypeable Haemophilus influenzae.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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group were 5-fold greater than in Control 1 group (79 vs 
14 Elisa Units [EU]/mL, P , 0.01). IgE NTHi OMP antibody 
was detected in all saliva, serum, and sputum samples in the 
moderate–severe COPD group and in all saliva and serum 
samples in Control 2 group. Salivary antibody levels were 
not significantly different. The level of antibody observed 
in the serum of the moderate–severe COPD group was 
17-fold higher than that observed in Control 2 group (257 
vs 15 EU/mL, P , 0.005). IgE NTHi OMP antibody levels 
in the sputum of the CB group were twice that observed in 
the moderate–severe COPD group (0.34 vs 0.17 EU/mL, 
P , 0.05), while the level of antibody in the serum of the 
moderate–severe COPD group was .3-fold that observed 
in the CB group (257 vs 79 EU/mL, P , 0.005). A similar 
level of antibody was observed in the saliva of both clinical 
groups (Table 2).
NTHi specific IgE antibodies to P6
IgE NTHi P6 antibodies were not detected in the saliva of any 
group and only in the sputum of the CB group (0.33 EU/mL). 
In serum, IgE NTHi P6 antibodies tended to be highest in 
the moderate–severe COPD group with both the CB and 
COPD groups being higher than their respective controls. 
This was only significant for the CB group (61 vs 10 EU/mL, 
P , 0.001) (Table 2).
Discussion
This study aimed to assess the extent to which IgE antibody 
directed against NTHi antigens was present in smokers 
with recurrent acute bronchitis with either minimal or 
  moderate–severe airways disease. Several characteristics 
were shared between these two groups. All were smokers or 
had recently smoked, and most had CB. While none had a 
long-standing history of ‘asthma’ or interval asthma, all but 
one had wheeze as part of their acute bronchitic episodes. The 
two groups differed in age and FEV1 as would be expected 
from the selection process.
In this cohort comparison study with age-matched controls 
without history of recurrent acute bronchitis, asthma, allergic 
disease, or smoking, 3 observations are made with respect to 
an IgE response to colonization with NTHi. First, in neither 
study group was there a significant difference between total 
IgE levels compared with age-matched controls.   However, 
given that those with moderate–severe COPD have a median 
level twice that of the age-matched control group and a level 
significantly higher than that of the CB group, it is reason-
able to conclude that continued intrabronchial inflammation 
over time is at least in part responsible for elevation in IgE 
noted in those with moderate–severe COPD. This concept 
is consistent with earlier findings27,28 and supported by the 
demonstrated increased upper respiratory tract coloniza-
tion in this study. Second, there is detectable IgE antibody 
directed against NTHi OMPs in serum and saliva of normal 
subjects, using assays that include a mix of OMP antigens 
and the purified P6 protein, a specific and conserved NTHi 
antigen.29 This observation is consistent with studies that 
show both systemic and local immune response to NTHi in 
normal subjects detected as IgA and IgG antibody,30 as well 
as, T cell sensitization.31 The detection of specific NTHi IgE 
antibody in age matched controls indicates that IgE antibody 
Table 2 Total Ige, Ige to nThi OMP, and Ige to nThi P6 in the CB group, moderate–severe COPD group, Control 1 group, and 
Control 2 group
Clinical groups Age-matched healthy controls
CB COPD Control 1 Control 2
Saliva Serum Sputum Saliva Serum Sputum Saliva Serum Saliva Serum
Total Ige (ng/mL)
  Mean ± se 5.0 ± 0.4* 438 ± 100+ 11.5 ± 1.6 8.5 ± 1.2c,* 992 ± 224+ 11.8 ± 1.7 5.4 ± 0.7 401 ± 92 4.0 ± 1.0c 490 ± 118d
  Median 4.8 297 11.4 8.4 784 9.6 5.4 290 2.8 401
  range 2.4–7.0 131–1172 4.1–21.3 2.2–20.6 112–3822 1.9–22.7 1.6–9.3 210–1093 1.1–9.4 119–1,199
OMP Ige (eUb/mL)
  Mean ± se 0.26 ± 0.05 79 ± 14e,# 0.34° ± 0.9 0.26 ± 0.04 257 ± 54d,# 0.17° ± 0.04 nDa 14 ± 4e 0.15 ± 0.03 15 ± 3d
  Median 0.19 80 0.25 0.16 202 0.15 12 0.13 15
  range 0.11–0.66 11–176 0.11–1.16 0.11–0.56 33–801 0.09–0.40 2–35 0.08–0.27 5–32
P6 Ige (eUb/mL)
  Mean ± se nD 61 ± 15f 0.33 ± 0.6 nD 182 ± 43 nD nD 10 ± 5f nDa 86 ± 36
  Median 36 0.25 122 7 55
  range 13–158 0.21–0.67 3–523 2–30 6–361
Notes: anD, not detectable; belisa Units; cP , 0.005; dP , 0.005; eP , 0.01; fP , 0.001; *P , 0.05; +P , 0.05; #P , 0.05; °P , 0.05.
Abbreviations: CB, chronic bronchitis; nD, not detectable; nThi, nontypeable Haemophilus influenzae; OMP, outer membrane protein; se, standard error.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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is a component of the immune response to inhaled NTHi 
  following intermittent colonization of the upper airways with 
antibody secreted from B lymphocytes within the bronchus 
mucosa.32 Third, specific antibody is increased in serum in 
both the CB and COPD groups compared with appropriate 
controls, with significantly higher anti-OMP IgE antibody 
in those with more severe disease. For the two study groups, 
the proportionate increase in specific antibody parallels the 
difference in total IgE levels. The finding of lower levels of 
specific NTHI IgE antibody in the sputum of the moderate–
severe COPD group compared with the CB group may reflect 
the binding of IgE to the surface of respiratory cells and 
NTHi in subjects with a higher bacterial load, consistent with 
  previous observations.19 Specific NTHi IgE antibody has been 
described in chronic airways disease,19,33 as has IgE antibody 
directed against other bacterial antigens.33–37 These earlier 
studies are largely isolated observations. Though limited 
to cross-sectional observations, the current study attempts 
to identify the profile of the immediate hypersensitivity 
response to NTHi by comparing subjects with mild and 
moderate–severe disease. Though these results may reflect 
change over time (and ‘early’ and ‘late’ smoking-related 
COPD), this study was not constructed to allow such conclu-
sions, and it is recognized that not all with mild disease will 
progress to severe COPD.13,14
What is the mechanism of increase  
in IgE and specific IgE antibody  
in smoking-related COPD?
Smoking has been suggested as a cause of high IgE levels 
found in smokers;28 however, in the current study most of the 
moderate–severe COPD group were not smoking at the time 
of the study. The mechanisms by which smoking raises IgE 
levels and the duration of the effect are unknown. A likely 
explanation is that the elevated IgE responses observed in this 
study reflect colonization of damaged airways, possibly by a 
number of bacteria.38 NTHi is the major pathogen colonizing 
damaged airways in COPD9,10 and acute exacerbations of 
COPD have been attributed to acquisition of ‘exacerbation 
isolates’ of NTHi39 and/or virus infection perturbing the 
host–parasite relationship involving NTHi.12,40 Many bacteria 
including NTHi stimulate polyclonal lymphocyte activation 
that could expand the IgE-secreting B cell population.41 
Colonization of damaged airways by NTHi favors a Th2 
cytokine response with production of IL-431,42,43 which, with 
IL-13, is expressed within the bronchus mucosa of smokers 
with CB.42 A sequence of signals involving IL-4 and IL-13 
followed by interaction of the B cell surface antigen CD40 
with its ligand (CD4OL) expressed on activated Th2 cells44 
leads to IgE secretion.
Does the production of Ige antibody  
to colonizing nThi have clinical 
relevance?
All forms of COPD commonly have a component of revers-
ible airways obstruction, and bronchial hyper-reactivity is 
often present in COPD that is unrelated to classical atopic 
asthma. It is reasonable to accept that in those with specific 
NTHi IgE antibody, mucus hypersecretion,4 bronchial 
hyperreactivity,45 and bronchospasm due to a combination of 
events in the bronchus mucosa with mast cell degranulation46 
and within the lumen with eosinophil degranulation,21,47 clini-
cally significant reversible airways obstruction is a signifi-
cant outcome. Oral immunotherapy of subjects with COPD 
with inactivated NTHi reduces the level of colonization of 
damaged airways by up to 3 logs,48 significantly reduces the 
incidence of acute wheezing bronchitis in subjects with CB,8 
reduces the severity of acute exacerbations,8,15,16 and reduces 
the use of antiasthma therapy (unpublished   observations). 
There is also evidence to suggest that this therapeutic 
approach stimulates a Th1 type response against chronic 
microbial infections.49 Recently it was demonstrated that 
NTHi oral immunotherapy prevented NTHi from penetrating 
into the terminal airways,15 and this was correlated with an 
enhanced circulating specific antigen reactive T cell response 
and a reduction in the level of salivary lysozyme,50 a marker 
of luminal inflammation in COPD.51 Prospective therapeutic 
studies aimed at reducing the intrabronchial load of NTHi, 
which correlate improvement of bronchial hyperreactivity 
and clinical bronchospasm with laboratory parameters of 
IgE-mediated hypersensitivity, are needed to determine 
more clearly the clinical relevance of specific IgE antibody 
in subjects with mild and severe COPD.
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